Mr Mfazo Hove Featured in Newsweek: GLP-1 Medications and Vision Loss
- Posted
- Medically Reviewed by: Mr Mfazo Hove, Consultant Ophthalmic Surgeon
- Author: Chris Dunnington
- Published: July 16, 2026
- Last Updated: July 16, 2026
Mr Mfazo Hove, Consultant Ophthalmic Surgeon and Medical Director of Blue Fin Vision®, has been invited by Newsweek to comment on new international research linking GLP-1 medications to a rare optic nerve condition that can cause sudden vision loss.
What the Research Found
The research, published in the Annals of Internal Medicine, examined whether people with type 2 diabetes taking GLP-1 receptor agonists such as semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) face a higher risk of ischaemic optic neuropathy. The study found a small increase in risk, equating to roughly three to four additional cases per 10,000 patients treated over 18 months. The researchers were careful to stress that this is an association rather than proof the medications cause the condition.
Mr Hove's Response: Vigilance, Not Alarm
Speaking to Newsweek, Mr Hove set out a measured, patient-focused response:
“The right response to this research is vigilance and monitoring, not alarm.”
He was equally clear that new symptoms should never be dismissed:
“Any sudden change in vision should be treated as a medical emergency. These symptoms are not always due to ischaemic optic neuropathy and often have other explanations, but they should never be ignored or left in the hope they settle.”
Mr Hove noted that any potential risk must be weighed against the well-established benefits of GLP-1 medications, which include improved blood sugar control, significant weight loss and a reduced risk of cardiovascular disease.
Vision Symptoms to Take Seriously
Patients taking a GLP-1 medication should be alert to any sudden or unexplained change in vision. Seek prompt assessment if you notice:
- Painless loss of vision or blurring in one eye
- Dimming of vision
- A change in colour perception
- A missing or shaded area within the field of view
Any of these warrants urgent assessment, whether or not the cause turns out to lie in the optic nerve. No one should stop a prescribed medication on the basis of a news report alone. Decisions of that kind should be made with your medical team, informed by your individual circumstances.
Read the Full Coverage
You can read Mr Hove’s full commentary in Newsweek here: Popular GLP-1 Weight Loss Drugs Linked to Risk of Sudden Vision Loss.
Concerned About Your Eye Health?
If you take a GLP-1 medication and notice any change in your vision, our consultant-led team can provide urgent evaluation of the optic nerve and wider visual system and advise you and your prescribing doctor on next steps. Book a consultation with Blue Fin Vision® across our London, Hertfordshire and Essex locations.
